Telmisartan reduces atrial arrhythmia susceptibility through the regulation of RAS–ERK and PI3K–Akt–eNOS pathways in spontaneously hypertensive rats

Canadian Journal of Physiology and Pharmacology

Volumn 93, Issue 8, 2015, Pages 657-665

  Wang, Wei wei ^a   Zhang, Fei Long ^a   Chen, Jian hua ^a   Chen, Xue hai ^a   Fu, Fa yuan ^a   Tang, Mi rong ^a   Chen, Liang long ^a  

^a FUJIAN MEDICAL UNIVERSITY   (China)

Author keywords

Angiotensin receptor blockers; Atrial fibrillation; Hypertension; Signaling pathway; Structural remodeling

Indexed keywords

ENDOTHELIAL NITRIC OXIDE SYNTHASE; MITOGEN ACTIVATED PROTEIN KINASE; PHOSPHATIDYLINOSITOL 3 KINASE; PROTEIN KINASE B; RAS PROTEIN; TELMISARTAN; VALSARTAN; ANGIOTENSIN 1 RECEPTOR ANTAGONIST; ANTIARRHYTHMIC AGENT; ANTIHYPERTENSIVE AGENT; BENZIMIDAZOLE DERIVATIVE; BENZOIC ACID DERIVATIVE; NOS3 PROTEIN, RAT;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; APOPTOSIS; ARTICLE; CONTROLLED STUDY; ECHOCARDIOGRAPHY; ELECTROPHYSIOLOGY; ENZYME REPRESSION; HEART ATRIUM ARRHYTHMIA; HEART ATRIUM ENLARGEMENT; HEART ATRIUM REMODELING; HEART HYPERTROPHY; HISTOLOGY; HYPERTENSION; MALE; MUSCLE CELL; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; RAT; SYSTOLIC BLOOD PRESSURE; WESTERN BLOTTING; ANIMAL; ARRHYTHMIAS, CARDIAC; BLOOD PRESSURE; CARDIAC MUSCLE CELL; COMPARATIVE STUDY; DISEASE MODEL; DRUG EFFECTS; ENZYMOLOGY; FIBROSIS; HEART RATE; METABOLISM; PATHOLOGY; PATHOPHYSIOLOGY; SIGNAL TRANSDUCTION; SPONTANEOUSLY HYPERTENSIVE RAT; TIME FACTOR; WISTAR KYOTO RAT;

ANGIOTENSIN II TYPE 1 RECEPTOR BLOCKERS; ANIMALS; ANTI-ARRHYTHMIA AGENTS; ANTIHYPERTENSIVE AGENTS; APOPTOSIS; ARRHYTHMIAS, CARDIAC; ATRIAL REMODELING; BENZIMIDAZOLES; BENZOATES; BLOOD PRESSURE; DISEASE MODELS, ANIMAL; EXTRACELLULAR SIGNAL-REGULATED MAP KINASES; FIBROSIS; HEART RATE; HYPERTENSION; MALE; MYOCYTES, CARDIAC; NITRIC OXIDE SYNTHASE TYPE III; PHOSPHATIDYLINOSITOL 3-KINASE; PROTO-ONCOGENE PROTEINS C-AKT; RAS PROTEINS; RATS, INBRED SHR; RATS, INBRED WKY; SIGNAL TRANSDUCTION; TIME FACTORS; VALSARTAN;

EID: 84938580409     PISSN: 00084212     EISSN: 12057541     Source Type: Journal    
DOI: 10.1139/cjpp-2014-0416     Document Type: Article

References (40)

1. Aldhoon, B., Melenovský, V., Peichl, P., and Kautzner, J. 2010. New insights into mechanisms of atrial fibrillation. Physiol. Res. 59(1): 1–12. PMID:19249911.
2. Benjamin, E.J., Levy, D., Vaziri, S.M., D’Agostino, R.B., Belanger, A.J., and Wolf, P.A. 1994. Independent risk factors for atrial fibrillation in a population-based cohort. The Framingham Heart Study. JAMA, 271(11): 840– 844. doi:10.1001/jama.1994.03510350050036. PMID:8114238.
3. Brilla, C.G., Pick, R., Tan, L.B., Janicki, J.S., and Weber, K.T. 1990. Remodeling of the rat right and left ventricles in experimental hypertension. Circ. Res. 67(6): 1355–1364. doi:10.1161/01.RES.67.6.1355. PMID:1700933.
4. Camm, A.J., Kirchhof, P., Lip, G.Y., Schotten, U., Savelieva, I., Ernst, S., et al. 2010. Guidelines for the management of atrial fibrillation: the Task Force for the Management of Atrial Fibrillation of the European Society of Cardiology (ESC). Eur. Heart J. 31(19): 2369–2429. doi:10.1093/eurheartj/ehq278.
5. PMID: 20802247.
6. Cardin, S., Li, D., Thorin-Trescases, N., Leung, T.K., Thorin, E., and Nattel, S. 2003. Evolution of the atrial fibrillation substrate in experimental congestive heart failure: angiotensin-dependent and -independent pathways. Cardiovasc. Res. 60(2): 315–325. doi:10.1016/j.cardiores.2003.08.014. PMID:14613861.
7. Cheng, S.M., Ho, T.J., Yang, A.L., Chen, I.J., Kao, C.L., Wu, F.N., et al. 2013. Exercise training enhances cardiac IGFI-R/PI3K/Akt and Bcl-2 family associated prosurvival pathways in streptozotocin-induced diabetic rats. Int. J. Cardiol. 167(2): 478–485. doi:10.1016/j.ijcard.2012.01.031. PMID:22341695.
8. Choisy, S.C., Arberry, L.A., Hancox, J.C., and James, A.F. 2007. Increased susceptibility to atrial tachyarrhythmia in spontaneously hypertensive rat hearts. Hypertension, 49(3): 498–505. doi:10.1161/01.HYP.0000257123.95372.ab. PMID: 17242301.
9. Dang, A., Zheng, D., Wang, B., Zhang, Y., Zhang, P., Xu, M., et al. 1999. The role of the renin–angiotensin and cardiac sympathetic nervous systems in the development of hypertension and left ventricular hypertrophy in spontaneously hypertensive rats. Hypertens. Res. 22(3): 217–221. doi:10.1291/hypres.22.217. PMID:10515445.
10. Fogari, R., Mugellini, A., Zoppi, A., Preti, P., Destro, M., Lazzari, P., et al. 2012. Effect of telmisartan and ramipril on atrial fibrillation recurrence and severity in hypertensive patients with metabolic syndrome and recurrent symptomatic paroxysmal and persistent atrial fibrillation. J. Cardiovasc. Pharmacol. Ther. 17(1): 34–43. doi:10.1177/1074248410395018. PMID:21335482.
11. Goette, A., Arndt, M., Rocken, C., Spiess, A., Staack, T., Geller, J.C., et al. 2000. Regulation of angiotensin II receptor subtypes during atrial fibrillation in humans. Circulation, 101(23): 2678–2681. doi:10.1161/01.CIR.101.23.2678. PMID:10851203.
12. Healey, J.S., Baranchuk, A., Crystal, E., Morillo, C.A., Garfinkle, M., Yusuf, S., et al. 2005. Prevention of atrial fibrillation with angiotensin-converting enzyme inhibitors and angiotensin receptor blockersa meta-analysis. J. Am. Coll. Cardiol. 45(11): 1832–1839. doi:10.1016/j.jacc.2004.11.070. PMID:15936615.
13. Hoyano, M., Ito, M., Kimura, S., Tanaka, K., Okamura, K., Komura, S., et al. 2010. Inducibility of atrial fibrillation depends not on inflammation but on atrial structural remodeling in rat experimental autoimmune myocarditis. Cardiovasc. Pathol. 19(5): 149–157. doi:10.1016/j.carpath.2009.07.002. PMID:19747850.
14. ILAR (Institute of Laboratory Animal Resources). 1996. Guide for the care and use of laboratory animals. NIH Publication No. 85-23 (revised 1996). National Academy Press, Washington, D.C. [Available from www.nap.edu/openbook.php?record_id=5140].
15. Imayama, I., Ichiki, T., Inanaga, K., Ohtsubo, H., Fukuyama, K., Ono, H., et al. 2006. Telmisartan downregulates angiotensin II type 1 receptor through activation of peroxisome proliferator-activated receptor γ. Cardiovasc. Res. 72(1): 184–190. doi:10.1016/j.cardiores.2006.07.014. PMID:16938288.
16. Iwasaki, Y.K., Nishida, K., Kato, T., and Nattel, S. 2011. Atrial fibrillation pathophysiology: implications for management. Circulation, 124(20): 2264–2274. doi:10.1161/CIRCULATIONAHA.111.019893. PMID:22083148.
17. Jibrini, M.B., Molnar, J., and Arora, R.R. 2008. Prevention of atrial fibrillation by way of abrogation of the renin–angiotensin system: a systematic review and meta-analysis. Am. J. Ther. 15(1): 36–43. doi:10.1097/MJT.0b013e31804beb59. PMID:18223352.
18. Kannel, W.B., Wolf, P.A., Benjamin, E.J., and Levy, D. 1998. Prevalence, incidence, prognosis, and predisposing conditions for atrial fibrillation: populationbasedestimates. Am.J.Cardiol.82(8A):2N-9N.doi:10.1016/S0002-9149(98)00583-9. PMID:9809895.
19. Kim, H.S., No, C.W., Goo, S.H., and Cha, T.J. 2013. An Angiotensin receptor blocker prevents arrhythmogenic left atrial remodeling in a rat post myocardial infarction induced heart failure model. J. Korean Med. Sci. 28(5): 700– 708. doi:10.3346/jkms.2013.28.5.700. PMID:23678261.
20. Kim, Y.M., Guzik, T.J., Zhang, Y.H., Zhang, M.H., Kattach, H., Ratnatunga, C., et al. 2005. A myocardial Nox2 containing NAD(P)H oxidase contributes to oxidative stress in human atrial fibrillation. Circ. Res. 97(7): 629–636. doi:10.1161/01.RES.0000183735.09871.61. PMID:16123335.
21. Korantzopoulos, P., Kolettis, T.M., Galaris, D., and Goudevenos, J.A. 2007. The role of oxidative stress in the pathogenesis and perpetuation of atrial fibrillation. Int. J. Cardiol. 115(2): 135–143. doi:10.1016/j.ijcard.2006.04.026. PMID: 16764958.
22. Kumagai, K., Nakashima, H., Urata, H., Gondo, N., Arakawa, K., and Saku, K. 2003. Effects of angiotensin II type 1 receptor antagonist on electrical and structural remodeling in atrial fibrillation. J. Am. Coll. Cardiol. 41(12): 2197–2204. doi:10.1016/S0735-1097(03)00464-9. PMID:12821247.
23. Lau, Y.F., Yiu, K.H., Siu, C.W., and Tse, H.F. 2012. Hypertension and atrial fibrillation: epidemiology, pathophysiology and therapeutic implications. J. Hum. Hypertens. 26(10): 563–569. doi:10.1038/jhh.2011.105. PMID:22129612.
24. Medi, C., Kalman, J.M., Spence, S.J., Teh, A.W., Lee, G., Bader, I., et al. 2011. Atrial electrical and structural changes associated with longstanding hypertension in humans: implications for the substrate for atrial fibrillation. J. Cardiovasc. Electrophysiol. 22(12): 1317–1324. doi:10.1111/j.1540-8167.2011.02125.x. PMID: 21736657.
25. Muscogiuri, G., Chavez, A.O., Gastaldelli, A., Perego, L., Tripathy, D., Saad, M.J., et al. 2008. The crosstalk between insulin and renin–angiotensin–aldosterone signaling systems and its effect on glucose metabolism and diabetes prevention. Curr. Vasc. Pharmacol. 6(4): 301–312. doi:10.2174/157016108785909715. PMID:18855718.
26. Oliveira, M., da Silva, M.N., Timoteo, A.T., Feliciano, J., Sousa, L., Santos, S., et al. 2009. Inducibility of atrial fibrillation during electrophysiologic evaluation is associated with increased dispersion of atrial refractoriness. Int. J. Cardiol. 136(2): 130–135. doi:10.1016/j.ijcard.2008.04.097. PMID:18676037.
27. Pretorius, L., Du, X.J., Woodcock, E.A., Kiriazis, H., Lin, R.C., Marasco, S., et al. 2009. Reduced phosphoinositide 3-kinase (p110alpha) activation increases the susceptibility to atrial fibrillation. Am. J. Pathol. 175(3): 998–1009. doi:10.2353/ajpath.2009.090126. PMID:19679877.
28. Psaty, B.M., Manolio, T.A., Kuller, L.H., Kronmal, R.A., Cushman, M., Fried, L.P., et al. 1997. Incidence of and risk factors for atrial fibrillation in older adults. Circulation, 96(7): 2455–2461. doi:10.1161/01.CIR.96.7.2455. PMID:9337224.
29. Richter, B., Derntl, M., Marx, M., Lercher, P., Gössinger, H.D. 2007. Therapy with angiotensin-converting enzyme inhibitors, angiotensin II receptor blockers, and statins: no effect on ablation outcome after ablation of atrial fibrillation. Am. Heart J. 153(1): 113–119. doi:10.1016/j.ahj.2006.09.006. PMID:17174648.
30. Schiffrin, E.L., Amiri, F., Benkirane, K., Iglarz, M., and Diep, Q.N. 2003. Peroxisome proliferator-activated receptors: vascular and cardiac effects in hypertension. Hypertension, 42(4): 664–668. doi:10.1161/01.HYP.0000084370.74777.B6. PMID:12874098.
31. Schmieder, R.E., Kjeldsen, S.E., Julius, S., McInnes, G.T., Zanchetti, A., and Hua, T.A. 2008. Reduced incidence of new-onset atrial fibrillation with angiotensin II receptor blockade: the VALUE trial. J. Hypertens. 26(3): 403–411. doi:10.1097/HJH.0b013e3282f35c67. PMID:18300848.
32. Selemidis, S., Sobey, C.G., Wingler, K., Schmidt, H.H., and Drummond, G.R. 2008. NADPH oxidases in the vasculature: molecular features, roles in disease and pharmacological inhibition. Pharmacol. Ther. 120(3): 254–291. doi:10.1016/j.pharmthera.2008.08.005. PMID:18804121.
33. Sheng, Z., Yao, Y., Li, Y., Yan, F., Huang, J., and Ma, G. 2013. Bradykinin preconditioning improves therapeutic potential of human endothelial progenitor cells in infarcted myocardium. PLoS One, 8(12): e81505. doi:10.1371/journal.pone.0081505. PMID:24312554.
34. Wilhelmsen, L., Rosengren, A., and Lappas, G. 2001. Hospitalizations for atrial fibrillation in the general male population: morbidity and risk factors. J. Intern. Med. 250(5): 382–389. doi:10.1046/j.1365-2796.2001.00902.x. PMID: 11887972.
35. Xu, D., Murakoshi, N., Tada, H., Igarashi, M., Sekiguchi, Y., and Aonuma, K. 2010. Age-related increase in atrial fibrillation induced by transvenous catheterbased atrial burst pacing: an in vivo rat model of inducible atrial fibrillation. J. Cardiovasc. Electrophysiol. 21(1): 88–93. doi:10.1111/j.1540-8167.2009.01591.x. PMID:19817931.
36. Xu, D., Murakoshi, N., Igarashi, M., Hirayama, A., Ito, Y., Seo, Y., et al. 2012. PPAR-gamma activator pioglitazone prevents age-related atrial fibrillation susceptibility by improving antioxidant capacity and reducing apoptosis in a rat model. J. Cardiovasc. Electrophysiol. 23(2): 209–217. doi:10.1111/j.1540-8167.2011.02186.x. PMID:21954843.
37. Xu, L., and Liu, Y. 2013. Administration of telmisartan reduced systolic blood pressure and oxidative stress probably through the activation of PI3K/Akt/ eNOS pathway and NO release in spontaneously hypertensive rats. Physiol. Res. 62: 351–359. PMID:23590610.
38. Yki-Jarvinen, H. 2004. Thiazolidinediones. N. Engl. J. Med. 351(11): 1106–1118. doi:10.1056/NEJMra041001. PMID:15356308.
39. Yu, Y., Fukuda, N., Yao, E.H., Matsumoto, T., Kobayashi, N., Suzuki, R., et al. 2008. Effects of an ARB on endothelial progenitor cell function and cardiovascular oxidation in hypertension. Am. J. Hypertens. 21(1): 72–77. doi:10.1038/ajh.2007.5. PMID:18091747.
40. Zhao, J., Li, J., Li, W., Li, Y., Shan, H., Gong, Y., et al. 2010. Effects of spironolactone on atrial structural remodelling in a canine model of atrial fibrillation produced by prolonged atrial pacing. Br. J. Pharmacol. 159(8): 1584–1594. doi:10.1111/j.1476-5381.2009.00551.x. PMID:20082611.